Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PTG-100

Other · developed by Protagonist Therapeutics

Phase 2 Most advanced trial (none active)
PTGX Developer
1 Registered trials

What is PTG-100?

PTG-100 is a drug studied in ulcerative colitis, with daily dosing over a 12-week treatment period.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Protagonist Therapeutics, Inc. (PTGX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02895100 Phase 2 Ulcerative Colitis Terminated PTGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis

More from Protagonist Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTGX page.

Follow PTGX, the company behind PTG-100

See PTGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.